Bharat Bijlee Limited (BOM:503960)
India · Delayed Price · Currency is INR 2,845.55
-106.75 (-3.62%)
At close: Jul 28, 2025
Verve Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 19,918 | 19,017 | 18,725 | 14,185 | 12,657 | 7,310 | Upgrade | |
Revenue Growth (YoY) | 10.30% | 1.56% | 32.00% | 12.07% | 73.14% | -21.29% | Upgrade |
Cost of Revenue | 14,648 | 13,858 | 13,834 | 10,453 | 9,535 | 5,200 | Upgrade |
Gross Profit | 5,270 | 5,159 | 4,890 | 3,732 | 3,122 | 2,111 | Upgrade |
Selling, General & Admin | 2,124 | 2,062 | 1,805 | 1,483 | 1,349 | 1,030 | Upgrade |
Other Operating Expenses | 1,431 | 1,424 | 1,353 | 1,074 | 928.17 | 713.48 | Upgrade |
Operating Expenses | 3,751 | 3,678 | 3,312 | 2,687 | 2,397 | 1,840 | Upgrade |
Operating Income | 1,520 | 1,480 | 1,578 | 1,045 | 724.81 | 270.54 | Upgrade |
Interest Expense | -118.5 | -124.8 | -190.51 | -217.14 | -209.63 | -168.88 | Upgrade |
Interest & Investment Income | - | - | 267.42 | 218.81 | 175.71 | 205.12 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 6.48 | 9.04 | 3.63 | 3.16 | Upgrade |
Other Non Operating Income (Expenses) | 441.4 | 434.6 | 31.33 | 40.81 | 40.86 | 43.74 | Upgrade |
EBT Excluding Unusual Items | 1,842 | 1,790 | 1,693 | 1,097 | 735.38 | 353.68 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 27.51 | 16.95 | 10.95 | 15.03 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 20.07 | 0.07 | -0.76 | -2.15 | Upgrade |
Pretax Income | 1,842 | 1,790 | 1,741 | 1,114 | 745.58 | 366.55 | Upgrade |
Income Tax Expense | 466.4 | 453.7 | 426.33 | 281.36 | 189.79 | 106.06 | Upgrade |
Net Income | 1,376 | 1,337 | 1,314 | 832.23 | 555.79 | 260.5 | Upgrade |
Net Income to Common | 1,376 | 1,337 | 1,314 | 832.23 | 555.79 | 260.5 | Upgrade |
Net Income Growth | 5.81% | 1.68% | 57.94% | 49.74% | 113.36% | -42.90% | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade |
Shares Change (YoY) | 0.00% | 0.00% | - | - | - | - | Upgrade |
EPS (Basic) | 121.73 | 118.24 | 116.29 | 73.63 | 49.17 | 23.05 | Upgrade |
EPS (Diluted) | 121.73 | 118.24 | 116.29 | 73.63 | 49.17 | 23.05 | Upgrade |
EPS Growth | 5.81% | 1.68% | 57.94% | 49.74% | 113.36% | -42.90% | Upgrade |
Free Cash Flow | - | 1,402 | 2,070 | 358.83 | -257.83 | 215.17 | Upgrade |
Free Cash Flow Per Share | - | 124.06 | 183.16 | 31.75 | -22.81 | 19.04 | Upgrade |
Dividend Per Share | - | 35.000 | 35.000 | 20.000 | 10.000 | 2.500 | Upgrade |
Dividend Growth | - | - | 75.00% | 100.00% | 300.00% | -60.00% | Upgrade |
Gross Margin | 26.46% | 27.13% | 26.12% | 26.31% | 24.67% | 28.87% | Upgrade |
Operating Margin | 7.63% | 7.79% | 8.43% | 7.37% | 5.73% | 3.70% | Upgrade |
Profit Margin | 6.91% | 7.03% | 7.02% | 5.87% | 4.39% | 3.56% | Upgrade |
Free Cash Flow Margin | - | 7.37% | 11.06% | 2.53% | -2.04% | 2.94% | Upgrade |
EBITDA | 1,729 | 1,673 | 1,705 | 1,152 | 829.74 | 353.54 | Upgrade |
EBITDA Margin | 8.68% | 8.80% | 9.11% | 8.12% | 6.55% | 4.84% | Upgrade |
D&A For EBITDA | 209.39 | 192.9 | 126.95 | 106.65 | 104.93 | 83 | Upgrade |
EBIT | 1,520 | 1,480 | 1,578 | 1,045 | 724.81 | 270.54 | Upgrade |
EBIT Margin | 7.63% | 7.79% | 8.43% | 7.37% | 5.73% | 3.70% | Upgrade |
Effective Tax Rate | 25.31% | 25.34% | 24.49% | 25.27% | 25.45% | 28.93% | Upgrade |
Revenue as Reported | 20,360 | 19,452 | 19,107 | 14,476 | 12,898 | 7,578 | Upgrade |
Advertising Expenses | - | - | 20.12 | 7.83 | 1.79 | 1.53 | Upgrade |
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.